Will you bet on these? Arrowhead Pharmaceuticals, Inc. (ARWR), Cloudera, Inc. (CLDR)

The shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and Cloudera, Inc. (NYSE:CLDR) were among the active stocks of the last trading sessions. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) declined to -3.85% closing at the price of $14.74 whereas the shares of Cloudera, Inc. (NYSE:CLDR) declined -6.04% with the decrease of -1.15 points closing at the price of $17.9. Arrowhead Pharmaceuticals, Inc. has currently increase 131.03% in its stock over the period of 6-months while its rival Cloudera, Inc. added 40.5% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.

Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is -44.1% while the ROI of Cloudera, Inc. (NYSE:CLDR) is -80.5%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, ARWR’s EBITDA Margin is -32.22 whereas CLDR’s is -13.15.

Both the profitability ratios suggest a mixed sentiment for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and Cloudera, Inc. (NYSE:CLDR).

EPS & Surprise Factor

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reported $-0.18/share EPS for the previous quarter where analysts were predicting an EPS to be $-0.18/share Thus meeting the analyst Estimates with a Surprise Factor of 0 Percent. While, Cloudera, Inc. (NYSE:CLDR) reported EPS of $-0.08/share in the last quarter. The analysts projected EPS of $-0.15/share depicting a Surprise of 46.7 Percent.

Taking a look at Earnings per Share, Cloudera, Inc. tends to be beating the analyst estimates more than Arrowhead Pharmaceuticals, Inc.. so CLDR is more profitable than ARWR.

Technical Analysis of Arrowhead Pharmaceuticals, Inc. & Cloudera, Inc.

Moving average convergence divergence (MACD) shows that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is on a PRICE RELATIVITY trend While Cloudera, Inc. (NYSE:CLDR) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Arrowhead Pharmaceuticals, Inc. was in BEARISH territory and Cloudera, Inc. was in BULLISH territory.

ARWR’s current statistics gauge that the stock candle is BEARISH with HIGH volatility. While CLDR’s candle is BEARISH with HIGH.

EPS Growth Rate: ARWR’s 7.33% versus CLDR’s 21.9%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is predicted at 7.33% while Cloudera, Inc. (NYSE:CLDR) stands at 21.9%. These numbers suggest that CLDR is more suitable investment in terms of EPS growth rate.

Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of ARWR stands at 8.7 while CLDR is at 1.6 whereas the debt ratio of the prior is 0.02 while the debt ratio of the later is 0.

The values of the both ratios suggest that ARWR is more suitable investment when the liquidity and risk is the main concern.

Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 1.7 for ARWR and 2.1 for CLDR which means ARWR has Buy rating whereas CLDR has Hold rating.

Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for ARWR is $23.3 which is 36.74% of its current price while CLDR has price target of 21.64 which is 17.28% of its current price.

Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

ARWR currently has price to earning P/E ratio of 0 whereas CLDR has 0 while the forward P/E ratio for the prior stands at 0 and for the later it depicts the value of 0.

The price to Book P/B for ARWR is 12.6, Price to Sale is at 99.22 and for CLDR these ratios stand at 9.18 and 7.